DK641787D0 - VIRUS VECTOR CODING A GLYCOPROTEIN FROM THE VIRUS RESPONSIBLE FOR AIDS, VACCINE COVERING THE VIRUS VECTOR OR GLYCOPROTEIN, AND ANTIBODY AGAINST THE GLYCOPROTEIN - Google Patents

VIRUS VECTOR CODING A GLYCOPROTEIN FROM THE VIRUS RESPONSIBLE FOR AIDS, VACCINE COVERING THE VIRUS VECTOR OR GLYCOPROTEIN, AND ANTIBODY AGAINST THE GLYCOPROTEIN

Info

Publication number
DK641787D0
DK641787D0 DK641787A DK641787A DK641787D0 DK 641787 D0 DK641787 D0 DK 641787D0 DK 641787 A DK641787 A DK 641787A DK 641787 A DK641787 A DK 641787A DK 641787 D0 DK641787 D0 DK 641787D0
Authority
DK
Denmark
Prior art keywords
glycoprotein
virus
virus vector
aids
responsible
Prior art date
Application number
DK641787A
Other languages
Danish (da)
Other versions
DK641787A (en
DK175613B1 (en
Inventor
Marie-Paule Kieny
Guy Rautmann
Jean-Pierre Lecocq
Simon Wain-Hobson
Marc Girard
Luc Montagnier
Original Assignee
Transgene Sa
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26225146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK641787(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR8605043A external-priority patent/FR2596771B1/en
Application filed by Transgene Sa, Pasteur Institut filed Critical Transgene Sa
Publication of DK641787A publication Critical patent/DK641787A/en
Publication of DK641787D0 publication Critical patent/DK641787D0/en
Application granted granted Critical
Publication of DK175613B1 publication Critical patent/DK175613B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Viral vector characterized in that it comprises at least a portion of the genome of a virus, a gene coding for one of the glycoproteins (gp) of the envelope of the virus responsible for AIDS, as well as the elements providing for the expression of said glycoprotein in cells.
DK198706417A 1986-04-08 1987-12-07 Virus vector encoding a glycoprotein from the virus responsible for AIDS, vaccine comprising the virus vector or glycoprotein, and antibody to the glycoprotein DK175613B1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
FR8605043A FR2596771B1 (en) 1986-04-08 1986-04-08 VIRAL VECTOR AND RECOMBINANT DNA ENCODING VIA GLYCOPROTEIN CAUSAL AGENT OF THE S.I.D.A, CELL CULTURE INFECTED WITH THIS VECTOR, PROCESS FOR PREPARING GLYCOPROTEIN, GLYCOPROTEIN OBTAINED, VACCINE AND ANTIBODY OBTAINED
FR8615106 1986-10-29
FR8615106A FR2606029B2 (en) 1986-04-08 1986-10-29 VIRAL VECTOR AND RECOMBINANT DNA ENCODING VIA GLYCOPROTEIN CAUSAL AGENT OF THE S.I.D.A, CELL CULTURE INFECTED WITH THIS VECTOR, PROCESS FOR PREPARING GLYCOPROTEIN, GLYCOPROTEIN OBTAINED, VACCINE AND ANTIBODY OBTAINED
FR8605043 1986-10-29
FR8700116 1987-01-08
PCT/FR1987/000116 WO1987006260A1 (en) 1986-04-08 1987-04-08 Viral vector coding for a glycoprotein of the virus responsible for a.i.d.s., vaccine and antibody

Publications (3)

Publication Number Publication Date
DK641787A DK641787A (en) 1987-12-07
DK641787D0 true DK641787D0 (en) 1987-12-07
DK175613B1 DK175613B1 (en) 2004-12-27

Family

ID=26225146

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198706417A DK175613B1 (en) 1986-04-08 1987-12-07 Virus vector encoding a glycoprotein from the virus responsible for AIDS, vaccine comprising the virus vector or glycoprotein, and antibody to the glycoprotein

Country Status (12)

Country Link
EP (1) EP0245136B1 (en)
JP (3) JP2719917B2 (en)
KR (1) KR960001819B1 (en)
AT (1) ATE103328T1 (en)
AU (1) AU604696B2 (en)
CA (1) CA1341353C (en)
DE (1) DE3789400T2 (en)
DK (1) DK175613B1 (en)
ES (1) ES2052589T3 (en)
FR (1) FR2606029B2 (en)
PT (1) PT84640B (en)
WO (1) WO1987006260A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
US6133029A (en) * 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
IL89567A0 (en) * 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
IL93599A0 (en) * 1989-03-03 1990-12-23 Microgenesys Inc Kit and/or composition for the prevention or treatment of aids
DE69033911D1 (en) * 1989-10-24 2002-03-14 Chiron Corp SYSTEM FOR RELEASING INFECTIOUS PROTEINS
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US6228608B1 (en) * 1991-02-28 2001-05-08 Aquila Biopharmaceuticals, Inc. Recombinant FIV glycoprotein 160 and P24 gag protein
FR2676071B1 (en) * 1991-05-02 1994-11-18 Transgene Sa NEW NON-CLeavABLE, SOLUBLE, HYBRID-FORMING GP160 VARIANT.
GB9215233D0 (en) * 1992-07-17 1992-09-02 Pitman Moore Inc Vaccines
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
FR2766091A1 (en) * 1997-07-18 1999-01-22 Transgene Sa ANTITUMOR COMPOSITION BASED ON MODIFIED IMMUNOGENIC POLYPEPTIDE WITH CELL LOCATION
EP1648931B1 (en) 2003-07-21 2011-02-09 Transgene S.A. Multifunctional cytokines
CN1304580C (en) * 2004-07-09 2007-03-14 楼伟 Surface glucoprotein gp160 of recombination expression human acquired immunity defact virus 1
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA867281B (en) * 1985-09-25 1987-05-27 Oncogen Vaccines and immunoassays for acquired immune deficiency syndrome
IL82104A0 (en) * 1986-04-08 1987-10-30 Usa Recombinant vaccinia virus expressing human retrovirus genes and method for producing htlb-iii envelope proteins

Also Published As

Publication number Publication date
EP0245136A1 (en) 1987-11-11
JPH08224090A (en) 1996-09-03
DE3789400D1 (en) 1994-04-28
DK641787A (en) 1987-12-07
JPH01500161A (en) 1989-01-26
DK175613B1 (en) 2004-12-27
CA1341353C (en) 2002-04-02
JP2743164B2 (en) 1998-04-22
ATE103328T1 (en) 1994-04-15
AU7234987A (en) 1987-11-09
WO1987006260A1 (en) 1987-10-22
ES2052589T3 (en) 1994-07-16
KR960001819B1 (en) 1996-02-05
AU604696B2 (en) 1991-01-03
JPH1059868A (en) 1998-03-03
FR2606029B2 (en) 1989-02-03
KR880701283A (en) 1988-07-26
DE3789400T2 (en) 1994-09-01
FR2606029A2 (en) 1988-05-06
PT84640B (en) 1989-11-30
EP0245136B1 (en) 1994-03-23
JP2719917B2 (en) 1998-02-25
PT84640A (en) 1987-05-01

Similar Documents

Publication Publication Date Title
DK641787D0 (en) VIRUS VECTOR CODING A GLYCOPROTEIN FROM THE VIRUS RESPONSIBLE FOR AIDS, VACCINE COVERING THE VIRUS VECTOR OR GLYCOPROTEIN, AND ANTIBODY AGAINST THE GLYCOPROTEIN
AU1225088A (en) Peptides having immunological properties 2-hiv-2
ATE118353T1 (en) RECOMBINANT HERPES SIMPLEX GB-GD VACCINE.
AU580059B2 (en) Vaccine against rabies and preparation process thereof
DK76688A (en) VACCINE CONTAINING F-PROTEIN FROM AIDS VIRUS
DK498387D0 (en) Viral DNA SEQUENCE
DK631387A (en) viral vector
ATE122396T1 (en) GIBBON LEUKEMIA VIRUS RECEPTOR.
ES2054841T3 (en) VIRAL VECTOR AND RECOMBINANT DNA CODING FOR ONE OR SOME STRUCTURE PROTEINS (HA, F AND / OR NP), OF A MORBILIVIRUS.
FI870501A0 (en) Method for producing an antigenic peptide or antigenic protein derived from the melanoma-associated antigen p97 and useful recombinant viruses, recombinant vectors and host cells.
CA2141670A1 (en) Peptides, analogues and mixtures thereof for detecting and eliciting antibodies to the e1 and e2 protein of rubella virus
TH33841A (en) Recombinant Avipox Virus Cell culture infected with this virus And a vaccine for poultry that is derivable from this virus
TH33841EX (en) Recombinant Avipox Virus Cell culture infected with this virus And a vaccine for poultry that is derivable from this virus
FR2657016B1 (en) PEPTIDES DERIVED FROM THE GLYCOPROTEIN ENVELOPE OF THE HIV-2 VIRUS, THEIR APPLICATIONS FOR THE DETECTION OF AN INFECTION DUE TO THIS VIRUS AND FOR VACCINATION AGAINST AIDS.
DE363414T1 (en) INTRANASAL IMMUNIZATION AGAINST A VIRUS INFECTION USING A VIRAL GLYCOPROTEIN VACCINE.